How to Get Addyi in Connecticut: Prescriptions, Telehealth, and Pharmacy Access

What Is Addyi and Why Is the Prescribing Process Different from Other Medications?

Addyi (flibanserin) is the only FDA-approved non-hormonal treatment for acquired, generalized HSDD in premenopausal women. It works on serotonin and dopamine receptors in the central nervous system rather than on reproductive hormones, which means the prescribing pathway involves a specific Risk Evaluation and Mitigation Strategy (REMS) rather than standard controlled-substance scheduling. The FDA approved flibanserin in August 2015 with the ADDYI REMS as a condition of approval because of the clinically significant interaction between flibanserin and alcohol, which can produce severe hypotension and syncope.

HSDD itself is not rare. Estimates from population surveys suggest roughly 8 to 10 percent of U.S. women meet diagnostic criteria for HSDD with associated distress, though only a small fraction receive any pharmacological treatment. One 2018 analysis published in the Journal of Sexual Medicine found that treatment gaps persist primarily because of prescriber unfamiliarity with the REMS process and patient hesitation to raise the topic. Understanding the pathway in Connecticut removes both barriers.

The REMS attestation is a one-time online enrollment that takes approximately 15 minutes. Once a prescriber completes it, they may write flibanserin for any eligible patient. Pharmacies that dispense the drug must also be REMS-certified, but this step is handled by the pharmacy, not the patient.

Does Connecticut Allow Telehealth Prescribing for Addyi?

Yes. Connecticut law explicitly permits synchronous audio-video telehealth consultations for new prescriptions, and flibanserin is not a controlled substance, so the stricter DEA in-person requirements for Schedule II through IV drugs do not apply. A licensed Connecticut provider who has completed the REMS attestation may evaluate a patient over video, confirm the HSDD diagnosis using validated tools such as the Female Sexual Distress Scale-Revised (FSDS-R), and transmit a prescription electronically to a local or mail-order pharmacy.

Connecticut General Statutes Section 19a-906 requires that telehealth encounters meet the same standard of care as in-person visits. In practice, this means the provider must review the patient's full medication list, document alcohol use history, and confirm that ALT and AST values are within normal limits before issuing the prescription. A quick 20 to 30-minute video visit is generally sufficient for established flibanserin candidates.

Patients who already have an in-person diagnosis of HSDD from a gynecologist or primary care physician may find that a telehealth-only platform is the fastest route to an initial prescription. Several national telehealth platforms licensed in Connecticut carry REMS-certified prescribers on staff and can coordinate pharmacy fulfillment in the same session.

Who Can Prescribe Addyi in Connecticut?

Any Connecticut-licensed prescriber who completes the REMS attestation may prescribe flibanserin. This includes MDs, DOs, advanced practice registered nurses (APRNs), and physician assistants (PAs). Connecticut APRNs with prescriptive authority operate under a collaborative agreement with a physician for the first three years of independent practice, but this does not restrict their ability to prescribe non-controlled medications like flibanserin once they are REMS-certified.

The Endocrine Society's clinical practice guidelines on female sexual dysfunction note that HSDD evaluation falls within the scope of any clinician trained to take a structured sexual history, apply the DSM-5 diagnostic criteria, and screen for contributing medical or psychiatric conditions. Gynecologists and women's health APRNs are the most common prescribers in practice, but internists and psychiatrists with REMS attestation are equally authorized.

Patients should ask their chosen provider two direct questions before booking: "Are you REMS-certified for Addyi?" and "Do you have experience diagnosing HSDD using a validated distress scale?" A provider who answers yes to both is prepared to move efficiently from evaluation to prescription.

What Labs and Screening Are Required Before Starting Addyi?

Baseline liver function testing is the only mandatory laboratory requirement before prescribing flibanserin. Specifically, ALT and AST must be within normal limits because flibanserin is extensively metabolized by CYP3A4 in the liver, and hepatic impairment raises plasma concentrations to levels that increase hypotension risk substantially. The FDA prescribing label contraindicates flibanserin in patients with any degree of hepatic impairment.

Beyond LFTs, the prescriber must document:

• A complete medication reconciliation screening for moderate-to-strong CYP3A4 inhibitors (fluconazole, ketoconazole, clarithromycin, several HIV antiretrovirals, and others), which are contraindicated with flibanserin.
• Alcohol use history with a commitment to abstain completely during treatment. The REMS counseling requirement specifically addresses this.
• Absence of hypotension at baseline, since the combination of flibanserin and alcohol can drop systolic blood pressure to dangerous levels even hours after the last drink.
• A positive FSDS-R score or equivalent validated measure confirming that low desire causes personal distress, which is necessary to meet the FDA-approved indication.

No hormonal panels are required by the REMS, though many clinicians order estradiol, FSH, and thyroid-stimulating hormone to rule out an organic hormonal cause of low desire before attributing symptoms to primary HSDD. A 2020 review in the Journal of Clinical Endocrinology and Metabolism recommends ruling out hypothyroidism and hyperprolactinemia in all women presenting with acquired sexual dysfunction, since these conditions are treatable and should be addressed before or alongside pharmacotherapy.

What Does the Clinical Evidence Say About Flibanserin Efficacy?

The key BEGONIA trial (N=1,378 to 24 weeks) demonstrated that premenopausal women taking flibanserin 100 mg nightly reported statistically significant increases in the number of satisfying sexual events (SSEs) compared with placebo, along with reductions in distress as measured by the FSDS-R. Published in the Journal of Sexual Medicine in 2014, BEGONIA showed a mean increase of approximately 0.5 SSEs per month above placebo, a modest but patient-reported meaningful difference for a condition with no prior pharmacological option.

The VIOLET trial (N=1,585) reported similar findings, with flibanserin-treated patients showing significant improvements on the Female Sexual Function Index desire domain compared with placebo (P<0.001). This trial is summarized in the FDA's medical review document and reinforced the conclusion that the drug's effect, while not dramatic in absolute magnitude, is real and clinically distinguishable from placebo in the population for which it is indicated.

Discontinuation rates due to adverse events in the clinical program ran approximately 13 percent for flibanserin versus 6 percent for placebo, with dizziness, somnolence, nausea, and fatigue as the leading reasons for stopping. The 2015 FDA Advisory Committee transcript documents this safety profile in detail and reflects the committee's ultimate determination that the benefit-risk balance is acceptable in the approved population when REMS requirements are followed.

A 2021 Cochrane review of psychological and pharmacological interventions for HSDD placed flibanserin as the only FDA-approved pharmacological agent in this indication and noted that combined pharmacological plus psychological intervention may produce larger benefit than either approach alone.

How Do Connecticut Pharmacies Handle Addyi Dispensing?

Retail pharmacies in Connecticut that are REMS-certified may dispense brand-name Addyi directly from stock or via next-day specialty order. Large chains including CVS, Walgreens, and regional independents are generally REMS-certified. Patients should call ahead to confirm before dropping off a prescription, since not every individual store location has completed the certification even if the chain as a whole participates.

The HealthRX clinical team uses the following three-step pharmacy verification framework for Connecticut patients:

1. Confirm REMS certification by asking the pharmacy directly: "Is this location certified to dispense Addyi under the ADDYI REMS program?"
2. If the local pharmacy is not certified, request an electronic transfer to a mail-order REMS-certified pharmacy. The prescriber can transmit the prescription directly.
3. If insurance coverage requires a specific pharmacy network, verify network participation before the prescription is sent to avoid delays.

Mail-order REMS-certified pharmacies typically ship to Connecticut addresses within 2 to 5 business days from receipt of a valid prescription. Cold-chain shipping is not required for flibanserin, so standard ground delivery is appropriate for most orders.

What About 503A Compounding Pharmacies in Connecticut?

Licensed 503A compounding pharmacies in Connecticut may compound flibanserin for individual patients under a valid prescription. 503A pharmacies operate under state pharmacy board oversight and federal law governing patient-specific compounding, as described in Section 503A of the Federal Food, Drug, and Cosmetic Act. Compounded flibanserin is not FDA-approved and carries no REMS certification, so the prescriber assumes responsibility for documenting the clinical rationale for compounding over the branded product.

Compounding may be relevant for patients who cannot tolerate a specific excipient in the commercial tablet or who require a different dose form for a documented medical reason. Connecticut's Board of Pharmacy maintains a list of licensed 503A pharmacies; patients can search that registry at portal.ct.gov to confirm a pharmacy's current licensure status before filling.

Prescribers considering compounded flibanserin should document the specific medical necessity, since FDA guidance on 503A compounding requires a patient-specific prescription and a legitimate clinical rationale beyond cost reduction alone.

Does Connecticut Medicaid Cover Addyi?

Connecticut Medicaid covers flibanserin with prior authorization (PA) for premenopausal women who meet the HSDD diagnostic criteria. The PA process requires the prescriber to submit clinical documentation confirming the DSM-5 diagnosis, FSDS-R score or equivalent distress measure, a medication reconciliation ruling out contraindicated drugs, and evidence that non-pharmacological interventions (counseling, relationship therapy) have been considered or attempted.

The Connecticut Medical Assistance Program formulary lists flibanserin under the specialty drug tier. PA approval timelines vary by managed care organization but typically run 5 to 14 business days for standard review or 24 to 72 hours for urgent clinical review. Prescribers who document distress scores and contraindication checks thoroughly before submission tend to see faster approval.

Private insurers in Connecticut are not required by state mandate to cover flibanserin, so coverage varies widely by plan. Patients with commercial insurance should request a formulary exception in writing if the drug is not listed, citing the FDA indication and the absence of alternative approved therapies for HSDD. Sprout Pharmaceuticals offers a savings program for commercially insured patients that may reduce out-of-pocket cost to $99 per month for eligible individuals.

How Long Does the Entire Process Take in Connecticut?

From first telehealth visit to medication in hand, the typical timeline runs 5 to 10 business days for most Connecticut patients. The breakdown:

• Telehealth consultation and REMS-compliant prescription: same day or within 24 hours of scheduling.
• Lab results (LFTs if not recently on file): 1 to 2 business days for most outpatient labs.
• REMS-certified pharmacy dispensing: 1 to 2 days in-store, 2 to 5 days mail-order.
• Insurance PA (if required): 5 to 14 days standard, 24 to 72 hours urgent.

Patients who have recent LFT results already on file and who are paying cash or using the manufacturer savings program can compress this to as few as 2 to 3 business days total.

A 2022 survey published in Sexual Medicine Reviews found that prescriber REMS completion was the single largest source of delay in flibanserin access, accounting for an average of 8 additional days when the treating provider had not yet registered. Choosing a telehealth platform or clinician who is already REMS-certified eliminates this delay entirely.

Can I Transfer an Existing Addyi Prescription to a Connecticut Pharmacy?

Yes. Flibanserin is not a controlled substance, so Connecticut pharmacy law permits outbound and inbound prescription transfers for non-controlled medications between licensed pharmacies. A patient moving to Connecticut or switching pharmacies within the state may ask their current REMS-certified pharmacy to transfer the remaining refills to a Connecticut REMS-certified pharmacy by phone or electronic transfer.

The receiving Connecticut pharmacy must itself be REMS-certified. If the receiving pharmacy is not certified, the patient should ask their prescriber to send a new prescription rather than attempting a transfer, since a non-certified pharmacy cannot legally dispense the drug regardless of the transfer status.

Connecticut General Statutes Section 20-616 governs prescription transfer rules in the state and confirms that non-controlled prescriptions may be transferred once between pharmacies, or multiple times if the original pharmacy retains a copy of the transfer record. Refills count separately; the prescriber may authorize up to 11 refills on a non-controlled prescription under Connecticut law.

What Prior Authorization Documentation Does Connecticut Require?

Connecticut Medicaid and most private payers requiring PA for flibanserin ask for a consistent set of documents. Collecting these before submitting the PA request reduces back-and-forth and speeds approval.

Required documentation typically includes:

• DSM-5 diagnosis code for HSDD (F52.0, hypoactive sexual desire dysfunction).
• Validated distress score: FSDS-R total score of 11 or higher indicates clinically significant distress per DeRogatis et al. (2008).
• Confirmation that the patient is premenopausal (FSH <25 IU/L or clinical documentation).
• Medication reconciliation confirming no concurrent moderate-to-strong CYP3A4 inhibitors.
• Liver function test results within normal limits (ALT, AST).
• Documentation that psychotherapy or sex therapy was offered, attempted, or clinically contraindicated.
• REMS attestation confirmation number for the prescribing clinician.

The American College of Obstetricians and Gynecologists Committee Opinion 213 recommends that clinicians treating female sexual dysfunction document the biopsychosocial context of the diagnosis, which satisfies most payer requests for clinical narrative accompanying the PA form.

Prescribers who use the Sprout Pharmaceuticals prior authorization support line (available through the ADDYI REMS portal) report faster turnaround on Medicaid PA requests when the support team assists with form completion and peer-to-peer review scheduling.